We are excited to announce that preliminary data from our Phase 1 AMPLIFY-201 study of our cancer vaccine ELI-002 2P have been published in @NatureMedicine. Read more here: elicio.com/press_releases…
Elicio Therapeutics
261 posts
Elicio Therapeutics
@ElicioTx
Elicio (Nasdaq: $ELTX) is advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers.
Joined April 2021
- Elicio's late-breaking poster presentation at the @sitcancer #SITC25 40th Anniversary Annual Meeting will highlight new immunogenicity data from ongoing Phase 2 AMPLIFY-7P trial of ELI-002 in patients with mKRAS-driven pancreatic cancer. Read more: bit.ly/4hPWZij $ELTX
00:00 - We are pleased to announce the completion of our previously announced merger with Angion Biomedica. Elicio Therapeutics will trade under the ticker “ELTX” on the Nasdaq starting Friday, June 2, 2023. To learn more, see press release here: bit.ly/3OKsSMO $ELTX
- Watch medical oncologist, @DrShubhamPant, discuss updated preliminary data including relapse-free survival findings from the AMPLIFY-201 study of our investigational #cancervaccine, ELI-002, presented at @AACR Special Conference on Pancreatic #Cancer brnw.ch/21wDln8
00:00 - We announced positive interim data at @ASCO from the Phase 1 study of our cancer immunotherapy in patients with mutant #KRAS tumors. The data demonstrate that our vaccine was able to elicit a robust immune response and reduce tumor biomarkers. Learn more: bit.ly/3oHvIHR
- This #WomensHistoryMonth, we're celebrating the incredible women at Elicio! From scientists and researchers to the dedicated professionals across every team, we recognize & value the contributions women make towards our shared mission of developing a therapeutic #CancerVaccine.
00:00 - Our research collaborator @MSKCancerCenter recently published an article based on preliminary Phase 1 data showing the potential of our lymph node targeted vaccine in patients with pancreatic or colorectal cancer. Read the article here: mskcc.org/news/vaccine-t…
- “We are extremely encouraged by the T cell immunogenicity data from the ongoing Phase 2 ELI-002 7P trial," commented Robert Connelly, CEO of Elicio. Learn about the recent T cell immunogenicity data from the ongoing Phase 2 ELI-002 7P trial: bit.ly/4guEwqP $ELTX
00:00 - We announced Phase 1 data demonstrating that ELI-002 induced a strong T-cell response in patients with mKRAS-driven cancers. This, plus new preclinical data on ELI-007 and ELI-008 in #BRAF and #p53, respectively, will be presented at #SITC2023. Read more: bit.ly/3sl7ncC
- We are excited to announce encouraging preclinical data highlighting TCR-T cell therapy with our AMP immunotherapy & CpG combination has been published in @AACR journal, Cancer Immunology Research. Read more here: brnw.ch/21wGo2G
- 2022 has been an incredible year of progress and development here at Elicio. We are thankful for our wonderful team and all of their hard work in the relentless pursuit of novel #immunotherapy development. From all of us at Elicio, we wish you a happy and healthy holiday season!
- Our CMO, Dr. Chris Haqq, was featured in a @GENbio article discussing our vaccine-based approach to addressing “undruggable” oncotargets using our AMP platform which delivers #immunotherapies to the lymph nodes - the "brain center" of the immune system:
- Our AMPLIFY-201 Phase 1 study on #CancerVaccine ELI-002 2P has been published in @Nature Medicine. Hear from our EVP/CMO, Dr. Christopher Haqq, on the preliminary data and what this could mean for patients with #SolidTumors. brnw.ch/21wGwqO
00:00 - “The idea that you can target KRAS is really exciting.” — Dr. Dougan, @DanaFarber @NBCNews featured our data published in @NatureMedicine & the potential of Elicio's KRAS-targeting vaccine to prevent recurrence of hard-to-treat #pancreaticcancers. nbcnews.to/416le4O $ELTX
